

CURRICULUM VITAE
The Johns Hopkins University School of Medicine



Albert P. Garcia-Romeu, Ph.D.

August 22, 2018

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

- 2014-present NIH Guest Researcher, Neuroimaging Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD
- 2015-present Research Associate, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

Personal Data

Behavioral Pharmacology Research Unit
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224-6823
Tel.: (410) 550-1972
Fax: (410) 550-0030
Email: AGarci33@jhmi.edu

Education and Training

- 1999-2003 B.A., Psychology / Philosophy, Tulane University, New Orleans, LA
- 2007-2010 M.A., Psychology, Sofia University, Palo Alto, CA
- 2010-2012 Ph.D., Psychology, Sofia University, Palo Alto, CA
- 2012-2015 Postdoctoral, Behavioral Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD

Professional Experience

- 2011-2012 Clinical Research Coordinator; Thrive Research, Los Altos, CA
- 2011-2012 Graduate Adjunct Teaching Faculty; Sofia University, Palo Alto, CA
- 2013-2014 Undergraduate Adjunct Teaching Faculty; Goucher College, Baltimore, MD
- 2012-2015 Postdoctoral Fellow, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
- 2014-present NIH Guest Researcher, Neuroimaging Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD
- 2015-present Research Associate, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

PUBLICATIONS:

Original Research [OR]

1. Barnert ES, Himelstein S, Herbert S, **Garcia-Romeu A**, Chamberlain LJ. Innovations in practice: Exploring an intensive meditation intervention for incarcerated youth. *Child Adol Ment Health*. 2014;19(1):69-73; Data Analysis, Manuscript Preparation.
2. Himelstein S, Saul S, **Garcia-Romeu A**, Pinedo D. Mindfulness training as an intervention for substance user incarcerated adolescents: A pilot grounded theory study. *Subst Use Misuse*. 2014;49(5):560-570; Data Analysis, Manuscript Preparation.
3. Johnson MW, **Garcia-Romeu A**, Cosimano MP, Griffiths RR. Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol*. 2014;23(11):983-992; Data Collection & Analysis, Clinical Care of Participants, Manuscript Preparation.
4. **Garcia-Romeu A**, Himelstein SP, Kaminker J. Self-transcendent experience: a grounded theory study. *Qualitative Research*. 2015;15(5):633-654
5. Himelstein S, Saul S, **Garcia-Romeu A**. Does mindfulness meditation increase effectiveness of substance abuse treatment with incarcerated youth? A pilot randomized controlled trial. *Mindfulness*. 2015;6(6):1472-80

6. **Garcia-Romeu A**, Griffiths RR, Johnson MW. Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction. *Curr Drug Abuse Rev.* 2015;7(3):157-164
7. Addy PH, **Garcia-Romeu A**, Metzger M, Wade J. The subjective experience of acute, experimentally-induced *Salvia divinorum* inebriation. *J Psychopharmacol* 2015;29(4):426-435; Data Analysis, Manuscript Preparation.
8. Johnson MW, **Garcia-Romeu A**, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. *Amer J Drug Alc Abuse.* 2017;43(1):55-60; Data Collection & Analysis, Clinical Care of Participants, Manuscript Preparation.
9. Johnson MW, **Garcia-Romeu A**, Johnson PS, Griffiths RR. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. *J Psychopharmacol.* 2017; 31(7):841-850; Study Design, Data Collection & Analysis, Manuscript Preparation.
10. Huhn, AS, **Garcia-Romeu A**, Dunn KE. Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions. *Frontiers in Psychiatry.* 2018; 9(34):1-7. Data Analysis, Manuscript Preparation.
11. Noorani T, **Garcia-Romeu A**, Swift TC, Griffiths RR, Johnson MW. Psychedelic Therapy for Smoking Cessation: Qualitative analysis of participant accounts. *J Psychopharmacol.* 2018; advanced online publication. Study Design, Data Collection & Analysis, Manuscript Preparation.
12. **Garcia-Romeu A**, Davis, AK, Griffiths RR, Erowid E, Erowid F, Johnson MW. Naturalistic psychedelic use associated with substance abuse remission: An online survey. *Manuscript in preparation.* Study Design, Data Collection & Analysis, Manuscript Preparation.
13. **Garcia-Romeu A**, Dunn KE, Griffiths RR. An online survey of *Mitragyna speciosa* (kratom) users: Motivations for use and perceived therapeutic potentials. *Manuscript in preparation.* Study Design, Data Collection & Analysis, Manuscript Preparation.
14. **Garcia-Romeu A**, Barrett FS, Carbonaro TC, May D, Johnson MW, Griffiths RR. Identifying optimal dosing for psilocybin pharmacotherapy. *Manuscript in preparation.* Study Design, Data Collection & Analysis, Manuscript Preparation.

Review Articles [RA]

1. **Garcia-Romeu A**. Self-transcendence as a measurable transpersonal construct. *J Transpersonal Psychol.* 2010;42(1):26-47.
2. **Garcia-Romeu A**, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. *Exper Clin Psychopharmacol.* 2016;24(4):229-268.
3. **Garcia-Romeu A**, Richards WA. Current perspectives on psychedelic therapy: Use of serotonergic hallucinogens in clinical interventions. *In Press.* *International Review of Psychiatry*, 2018.

Book Chapters, Monographs [BC]

1. **Garcia-Romeu A**, Tart CT. (2013). Altered states of consciousness and transpersonal psychology. In H. Friedman & G. Hartelius (Eds.), *The Wiley-Blackwell Handbook of Transpersonal Psychology* (pp. 121-140). Chichester, West Sussex, UK: Wiley-Blackwell.
2. **Garcia-Romeu A**, Antoine DG. Hallucinogen-related disorders. *The Johns Hopkins Phipps Psychiatry Guide*. Johns Hopkins Point of Care Information Technology Center, Baltimore, MD. October, 2014.

Other Publications:

Guidelines/Expert Opinion [GL]

1. **Garcia-Romeu A**. Making your mark in the psychedelic renaissance. *MAPS Bulletin.* 2014;24(1):10-13.

Media Releases or Interviews [MR]

1. Stromberg J. (2014, Dec. 22). Scientists Think Shrooms Might be a Cure for Drug Addiction & Clinical Depression. Retrieved from <https://www.vox.com/>
2. Maughan T. (2015, June 15). Could Psychedelic Drugs Make Smokers Quit? Retrieved from <http://www.bbc.com>
3. Perry E. (2016, February). LSD: My Life Saving Drug. *Gentlemen's Quarterly (GQ)*, 94-99.
4. Lopez G, Zarracina J. (2016, Dec. 1). The Fascinating, Strange Medical Potential of Psychedelic Drugs Explained in 50+ Studies. Retrieved from <https://www.vox.com/>
5. Radcliffe S. (2016, Dec. 19). Illegal Drugs are Now Used as Medicine. Retrieved from <http://www.healthline.com>
6. Lowery D. (Director). (May 2, 2017). Addiction: A Psychedelic Cure? [Television series episode]. In Ron Howard & Brian Grazer (Producers), *Breakthrough*. National Geographic.

FUNDING

EXTRAMURAL Funding

Research Extramural Funding

Current

- 07/21/15–11/21/21 A Randomized Controlled Trial of 5-HT_{2A} Agonist Psilocybin for Tobacco Dependence
Sponsor: Heffter Research Institute
Total direct cost: \$680,000
PI: Matthew W. Johnson, Ph.D.
Role: Co-Investigator; 90% effort.
Notes: I helped design and procure funding for this study, and am now charged with execution of recruitment, participant screening, clinical care, data collection, data management, and future data analysis and manuscript preparation.
- 01/01/19 – 12/31/21 A Pilot Study of 5-HT_{2A} Agonist Psilocybin in Patients with Mild Cognitive Impairment or Early Alzheimer's Disease
Sponsor: Council on Spiritual Practices / Heffter Research Institute
Total direct cost: \$265,000
PIs: Albert Garcia-Romeu, Ph.D. & Paul Rosenberg, M.D.
Notes: We received initial funding for this grant in May, 2018 and are in the process of acquiring requisite approvals from the Johns Hopkins IRB, FDA, and DEA to conduct the study.

Pending

- 12/01/18-11/30/20 A Human Laboratory Study of Dextromethorphan/Quinidine Effects on Cigarette Smoking
1 R21 DA047428-01
Sponsor: NIH/NIDA
Total direct cost: \$275,000
PI: Albert Garcia-Romeu, Ph.D.
Notes: 20% effort. This study will examine whether dextromethorphan/quinidine, a widely available medication with known safety, which has been shown to reduce nicotine self-administration in rats, attenuates ad-lib smoking and craving in non-treatment seeking smokers in the laboratory. Impact score 33. Awaiting Council Review in October, 2018.

Previous

- 02/01/81 – 06/30/16 Human Behavioral Pharmacology and Substance Abuse
T32 DA007209
Sponsor: NIH/NIDA
PI: George E. Bigelow, Ph.D.
Role: Postdoctoral Fellow/Trainee
Notes: I was a trainee at the Behavioral Pharmacology Research Unit for 3 years under this scientific mentoring grant, and have since transitioned to a mentoring role for current fellows.
- 07/01/84 – 02/28/18 Clinical Pharmacology/Mechanisms of Action of Emerging Abused Drugs (Club Drugs)
R01 DA003889
Sponsor: NIH/NIDA
PI: Roland R. Griffiths, Ph.D.
Role: Postdoctoral Fellow/Research Associate
Notes: I provide participant clinical care, postdoctoral mentoring, and research support for projects under this grant.

CLINICAL ACTIVITIES

Clinical Focus

During my doctoral education I received clinical training in palliative care with hospice patients, as well as teaching meditation and conducting research with incarcerated youth from diverse backgrounds. At Johns Hopkins I have conducted over three hundred counseling sessions consisting of cognitive-behavioral therapy and mindfulness-training for smoking cessation with several dozen treatment-seeking smokers, and have additionally safely overseen more than 60 moderate and high-dose hallucinogen sessions administering psilocybin to human subjects at our laboratory.

EDUCATIONAL ACTIVITIES

Teaching

Classroom instruction

01/12 - 05/12 Adjunct, Graduate (Ph.D.), Social Psychology, Sofia University, Palo Alto, CA.
01/12 - 05/12 Adjunct, Graduate (Ph.D.), Cognitive Psychology, Sofia University, Palo Alto, CA.
09/13 - 06/14 Adjunct, Undergraduate, Cognitive Studies, Goucher College, Baltimore, MD.

Mentoring

Pre-doctoral Advisees /Mentees

2015-2016 Brennan Kersgaard, B.A., co-author RA2
2015-2017 Toni White, B.A., Research Assistant, Johns Hopkins Medicine.

Thesis committees

2015 Natalie Roberts, M.A., Towards the Development of an Integrative Measure of Spontaneous Cephalocaudal Paresthesia, External Committee Member, Macquarie University, Sydney, Australia.
2016-present Felipe Landaeta Farizo, Ph.D.(c), Experiences of Transformation in Holotropic Breathwork: An Interpretive Phenomenological Analysis, External Committee Member, California Institute of Integral Studies, San Francisco, CA.

Educational Demonstration Activities to external audiences

03/10/16 Clinical and Translational Research with Hallucinogens. Invited mentoring presentation to under-represented biomedical graduate students in the Translational Research Training in Addictions for Racial/Ethnic Minorities At The City College of New York and Columbia University Medical Center, (TRACC) New York, NY.

RESEARCH ACTIVITIES

Research Focus

I am an early career investigator trained in psychology and behavioral pharmacology, with strong interests in clinical research, addiction treatment, and smoking cessation. My doctoral work explored the phenomenology and persisting effects of spiritual experiences, and the ways in which these may be leveraged to enhance psychological well-being. This included applied research studying effects of mindfulness meditation in incarcerated youth. At Johns Hopkins, under the mentorship of Drs. Matthew Johnson and Roland Griffiths, I began studying the psychopharmacology of hallucinogens with an emphasis on their potential as aids in smoking cessation and addiction treatment. I am currently forming independent lines of research as a Principal Investigator, with a focus on novel treatments for smoking cessation, opioid overdose prevention, and novel psychoactive substances.

Research Program Building

2015-Present Co-Investigator, Smoking Cessation with 5-HT_{2A} Agonist Psilocybin and Cognitive Behavioral Therapy; Our work in this area was the first to examine use of a serotonergic hallucinogen for smoking cessation, and represents the first published research on a 5-HT_{2A} agonist for addiction treatment in over 40 years. Our favorable pilot results led to collaboration with Dr. Elliot Stein at the National Institute on Drug Abuse Intramural Research Program, running an inter-institutional randomized clinical trial including neuroimaging data collection, which is currently underway. To conduct this research I was appointed to the NIH as a Guest Researcher, and am receiving training in functional neuroimaging. With colleagues at BPRU, I am part of a team of researchers who are actively examining psilocybin as a potential therapeutic agent. We constitute one of four laboratories in the U.S. currently working in this area.

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

02/01/17-Present Member of Student/Scholar Pipeline Workgroup, Department of Psychiatry and Behavioral Sciences (DPBS) Faculty Under-Represented In Medicine Task Force (UIM-TF); convened to make recommendations to the DPBS Director about strategies to advance recruitment, retention, and promotion of diverse faculty in DPBS and metrics to monitor progress.

Journal peer review activities

2013-Present International Journal of Transpersonal Studies
2014 Current Drug Abuse Reviews
2014-2015 Qualitative Research
2014-Present Journal of Psychoactive Drugs
2015-2016 Psychopharmacology (Berlin)
2015-2016 Archives of Gerontology and Geriatrics
2015-2016 The American Journal on Addictions
2015-2016 Journal of Psychopharmacology (Oxford, England)
2015-2016 Psychiatry Research
2015-Present Preventive Medicine
2016-Present Drug and Alcohol Dependence
2016-Present The American Journal of Drug and Alcohol Abuse
2017 Cannabis and Cannabinoid Research
2017 Journal of Nervous and Mental Disease
2017 Experimental and Clinical Psychopharmacology
2017 Journal of Addiction Medicine
2017-Present Neuropharmacology
2018 Neuroscience & Biobehavioral Reviews

Professional Societies

2009-present Affiliate, American Psychological Association, Division 24, Theoretical and Philosophical Psychology
2011-present Member, American Psychological Association, Division 5, Qualitative Inquiry in Psychology
2012-present Affiliate, American Psychological Association, Division 32, Humanistic Psychology
2013-present Affiliate, American Psychological Association, Division 28, Psychopharmacology & Substance Abuse
2013-present Associate Member, College on Problems of Drug Dependence (CPDD)
2014-present Member, Society for Research on Nicotine and Tobacco (SRNT)
2015-Present College on Problems of Drug Dependence (CPDD), Under-Represented Populations (URPOP) Committee member; Promoting diversity in substance abuse research and scholarship by supporting racial and ethnic minority students and early career researchers in CPDD.

Conference Organizer

02/02/12 Spirituality and Psychology Conference, Menlo College, Atherton, CA. Abstract Submission Reviewer; Evolution of Consciousness panel session organizer.

Session Chair

05/14/15 Qualitative psychopharmacology: Exploring the subjective effects of hallucinogens and their healing potentials. Chair, Symposium presented at the Society for Qualitative Inquiry in Psychology Annual Conference, City University of New York, NY.

Consultantships

2015-2016 Private Consultant / Expert Witness, Department of Defense, Defense Legal Services Agency, Washington Hearing Office, Arlington, VA.

RECOGNITION

Awards, Honors

1999-2003 Tulane University Merit Scholarship
2012-2015 National Institutes of Health, Ruth L. Kirschstein National Research Service Award
2014 American Psychological Association, Interdivisional Mentoring Award
2014 NIDA Director's Travel Award

- 2015 International Forum on Consciousness Scholarship
- 2016 Association for Medical Education and Research in Substance Abuse (AMERSA) Travel Award
- 2017 NIDA/NIAAA Early Career Travel Award for APA Div 28 (Psychopharmacology)/ Div 50 (Addiction)
- 2018 2018 Journal of Psychopharmacology Prize (Most cited manuscript of 2014).
- 2018-2020 National Institutes of Health Loan Repayment Program (LRP) NIDA Extramural Clinical Research Award.

Invited Talks / Panels

JHMI/Regional

- 2014 Psychedelic-facilitated treatment of tobacco addiction. Invited talk presented at the NIDA IRP, Baltimore, MD.
- 2015 Researching hallucinogens as an aid in the treatment of addiction. Invited talk presented at the Mind the Gap lunch series for physicians in training at the Johns Hopkins University School of Medicine, Baltimore, MD.
- 2015 An Overview of Psilocybin Research from Johns Hopkins School of Medicine. Invited talk presented to the Mycological Association of Washington, DC.
- 2016 Clinical Potentials of Psilocybin in Psychiatry. Invited talk presented at the Yale University School of Medicine, New Haven, CT.
- 2016 The Re-emergence of Psychedelics in Clinical Science. Invited talk presented to the College of Psychiatric and Neurologic Pharmacists at the University of Maryland School of Pharmacy, Baltimore, MD.
- 2018 Psychedelics as therapeutics: An update on current research. Invited talk presented to the College of Psychiatric and Neurologic Pharmacists at the University of Maryland School of Pharmacy, Baltimore, MD.
- 2018 Psilocybin in the Treatment of Mood and Substance Use Disorders. Invited talk presented at the Sleeping Octopus Assembly on Psychedelics, Pittsburgh, PA.

National

- 2013 Psilocybin in the Treatment of Smoking Addiction. Invited talk presented at the 7th annual Horizons: Perspectives on Psychedelics Conference, New York, NY.
- 2017 Exploring Psilocybin as a Tool for Modern Psychology and Medicine. Invited talk presented to the Puget Sound Mycological Society at the University of Washington, Seattle, WA.
- 2018 Psilocybin as an Aid in the Treatment of Addictions. Invited talk presented at the Portland Psychedelic Symposium, Portland, OR.
- 2018 A New Era of Treating Substance Use Disorders with Psychedelics. Invited symposium presented to the American Academy of Addiction Psychiatry 29th Annual Meeting, Bonita Springs, FL.

International

- 2013 The Future of Psychedelic Research: What's next? Invited panel at the biennial International Drug Policy Reform Conference, Denver, CO.
- 2015 What's the Latest Psychedelic Research Telling Us? Invited panel at the biennial International Drug Policy Reform Conference, Washington, DC.
- 2017 Developing Psilocybin as a Potential Pharmacotherapy: Identifying optimal dosing parameters. Invited talk presented at the 3rd International Psychedelic Science Conference, Oakland, CA.
- 2017 New Directions in Clinical Research with Psychedelics. Invited talk presented at the University of Toronto.
- 2017 Psychedelics as Change Agents in Addiction and Mood Disorders. Invited symposium presented at the Society for the Study of Addiction Annual Conference, Newcastle upon Tyne, England.

OTHER PROFESSIONAL ACCOMPLISHMENTS

Selected Posters

1. **Garcia-Romeu A.** (2009, October). Self-transcendence, molecular genetics, and the brain. Poster presented at the Science and Nonduality Conference, San Rafael, CA.
2. **Garcia-Romeu A.** (2010, April). Self-transcendence, conceptualization, and methodology: State of the science. Poster presented at the University of Arizona's 9th biennial Toward a Science of Consciousness Conference, Tucson, AZ.
3. Barnert ES, Himelstein S, Herbert S, **Garcia-Romeu A**, Chamberlain, LJ. (2012, January). An intensive meditation course for incarcerated youth: Does it make a difference? Poster presented at the American Pediatric Association's Pediatric Care Conference, Monterey, CA.
4. Addy PH, **Garcia-Romeu A**, Metzger M. (2012, September). Scientific exploration of subjective experience: Salvia divinorum. Poster presented at the University of Pennsylvania's Psychedemia Conference, Philadelphia, PA.
5. Addy PH, **Garcia-Romeu A**, Metzger M. (2013, April). The phenomenology of Salvia divinorum inebriation. Poster presented at the Psychedelic Science Conference, Oakland, CA.

6. **Garcia-Romeu A**, Johnson MW, Griffiths RR. (2013, June). Examining the psychological mechanisms of psilocybin assisted smoking cessation treatment: A pilot study. Poster presented at the 75th annual meeting of the College on Problems of Drug Dependence, San Diego, CA.
7. **Garcia-Romeu A**, Griffiths RR, Johnson MW. (2014, June). Psychedelic-facilitated smoking cessation: an online survey. Poster presented at the meeting of the College on Problems of Drug Dependence in San Juan, Puerto Rico.
8. **Garcia-Romeu A**. (2014, August). Self-transcendence: Measurement and experience. Poster presented at the American Psychological Association Convention in Washington, DC.
9. **Garcia-Romeu A**, Griffiths RR, Johnson MW. (2015, February). Psilocybin-occasioned mystical experience in the treatment of tobacco dependence. Poster presented at the Society for Research on Nicotine and Tobacco Annual Meeting in Philadelphia, PA.
10. **Garcia-Romeu A**, Noorani T, Griffiths RR, Johnson MW. (2015, June). Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and participant accounts. Poster presented at the College on Problems of Drug Dependence Annual Meeting in Phoenix, AZ.
11. **Garcia-Romeu A**, Griffiths RR, Johnson MW. (2016, June). Psychedelic-associated addiction remission: An online survey. Poster presented at the College on Problems of Drug Dependence Annual Meeting in Palm Springs, CA.
12. **Garcia-Romeu A**, Barrett FS, Johnson MW, Griffiths RR. (2017, June). Developing psilocybin as a potential pharmacotherapy: Identifying optimal dosing parameters. Poster presented at the College on Problems of Drug Dependence Annual Meeting in Montreal, Canada.
13. **Garcia-Romeu A**, Fedota JR, Stein EA, Griffiths RR, Johnson, MW. (2018, February). Psilocybin mediated reductions in smoking urges. Poster presented at the Society for Research on Nicotine and Tobacco Annual Meeting in Baltimore, MD.
14. McKenna MR, Fedota JR, **Garcia-Romeu A**, Griffiths RR, Johnson, MW, Stein EA. (2018, May). Psilocybin improves cognitive control and down-regulates parietal cortex in treatment-seeking smokers. Poster presented at the Society of Biological Psychiatry Annual Meeting in New York, NY.
15. Henningfield JE, Raffa RB, **Garcia-Romeu A**, Doshi TL. (2018, June). Kratom and its Mitragynines in the Opioid Crisis: A Path to or Away from Opioids? Poster presented at the College on Problems of Drug Dependence Annual Meeting in San Diego, CA.
16. **Garcia-Romeu A**, Dunn KE, Griffiths RR. (2018, June). A survey study characterizing use of kratom (*Mitragyna speciosa*). Poster presented at the College on Problems of Drug Dependence Annual Meeting in San Diego, CA.
17. Henningfield JE, Brown LS, Comer SD, **Garcia-Romeu A**, Hatsukami DL, Furr-Holden D. (2018, December). Increasing Minority Participation and Diversity in ACNP Meetings and Membership: 2018 Status and Recommendations: Barriers and Best Practices. Poster presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, FL.

Oral/Podium Presentations

1. **Garcia-Romeu A**. (2012, April). Towards a general theory of self-transcendence. Paper presented at University of Arizona's 20th annual Towards a Science of Consciousness Conference, Tucson, AZ.
2. **Garcia-Romeu A**, Johnson MW, Griffiths RR. (2013, April). Psilocybin in the treatment of smoking addiction: Psychological mechanisms and participant accounts. Paper presented at the 2nd International Psychedelic Science Conference, Oakland, CA.
3. **Garcia-Romeu A**. What can psychedelics teach us about consciousness? (2014, April) Paper presented at the 2014 Toward a Science of Consciousness Conference in Tucson, AZ.
4. **Garcia-Romeu A**, Griffiths RR, Johnson MW. (2016, November). Psychedelic-associated addiction remission: An online survey. Paper presented at the 40th annual Association for Medical Education and Research in Substance Abuse (AMERSA) national conference in Washington, DC.

Community Services

2008-2009	Volunteer Counselor/Mentor, Vision Youth, Log Cabin Boys' Ranch, La Honda, CA. I mentored incarcerated boys aged 14 to 18, leading nature hikes, teaching mindfulness meditation and yoga.
2010-2012	Grief Counselor / Palliative Care, Pathways Hospice, Sunnyside, CA. I performed palliative counseling and sat vigil with patients at the end of life, and provided bereavement support to families.
2014-Present	Volunteer Shopper / Meal Delivery, Meals on Wheels of Central Maryland, Baltimore, MD. I deliver meals to homebound seniors and disabled persons locally in East Baltimore, and assist in grocery shopping for this population weekly.